---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-019620"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T02:36:14.994938+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ionis announces positive Phase 3 Essence study of olezarsen in moderate hypertriglyceridemia

## Summary
- Primary endpoint met: placebo-adjusted 61% (80 mg) and 58% (50 mg) reduction in TG at 6 months (p<0.0001).
- Met all key secondary endpoints; majority of participants achieved normal TG <150 mg/dL.
- Favorable safety profile; most common AE was mild injection site reactions.
- Study enrolled 1,478 participants with moderate HTG on standard-of-care lipid-lowering therapy.
- Pivotal Phase 3 CORE and CORE2 data in sHTG expected Q3 2025; potential sNDA filing by year-end.

## SEC filing metadata
- accession: 0001140361-25-019620
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/0001140361-25-019620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125019620/ef20049265_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-019620
- JSON: https://secwatch.observer/filing/0001140361-25-019620.json
- Plain text: https://secwatch.observer/filing/0001140361-25-019620.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.